About 80% of NTC sales are coming from about 70 foreign markets, both though direct sales and commercial partnerships with major pharma companies. Main NTC therapeutic areas are Ophthalmology, Gastro-Metabolism, Pediatrics, Gynecology. Since its foundation, NTC enjoyed a steady growth (almost tripling the turnover since 2014) supported by substantial investments in R&D, which generated a very promising product pipeline. The first drug of this new generation to hit the market is Leviosa (a novel combination of antibiotic and anti-inflammatory collyrium) aimed at post-surgical ophthalmic treatments. Other launches are expected in the next 2-3 years.